Corporate investment in artificial intelligence has reached hundreds of billions of dollars, and some global healthcare groups are already reporting AI linked benefits in earnings. That shift in spending puts a spotlight on UK healthcare AI stocks that could benefit if hospitals and drug makers keep leaning into this technology. This article highlights three companies from our AI focused healthcare screener that investors may want on their watchlist.
The three stocks covered below are only a small sample from this theme. The full screen surfaced 6 more AI focused healthcare companies with equally compelling narratives that are not discussed in this article. To see the broader opportunity set and quickly identify which ideas best fit your own view on risk, time horizon, and business model, head straight to the Transformative Artificial intelligence (AI) Healthcare Stocks screener.
Haleon is a pure play consumer health group whose push into AI comes through a collaboration with Microsoft that uses data tools to sharpen decisions rather than sell software, applied across a portfolio spanning oral care, pain relief, vitamins and respiratory products.
Haleon generates about £3.8b of revenue from North America, £4.7b from Europe, the Middle East, Africa and Latin America, and £2.6b from Asia Pacific, backed by a market value of roughly £28.1b.
For an AI healthcare theme that is often dominated by diagnostics and drug discovery, Haleon offers something different. It is using AI inside a global consumer portfolio to improve how everyday health products are planned, priced and supplied, which can matter a lot to earnings quality over time.
“Delivery of the £800m gross cost savings and operating model programs, including 27% SKU and 26% formulation reductions and early benefits from AI tools that have improved forecast accuracy by 5% to 6%, underpins the recent 140 basis points gross margin expansion and provides a visible path for further net margin and earnings improvement.”
The real swing factor is how one unresolved pressure on its growth targets interacts with these efficiency gains to shape future profitability.
That swing factor is exactly what the full narrative for Haleon unpacks, showing where Haleon’s AI savings could decouple earnings quality from headline growth targets.
Abingdon Health is a York based diagnostics specialist that leans into AI through its Appdx smartphone reader and digital health services, while still earning most of its income from more traditional work. It generated about £5 million from contract development, £4.1 million from regulatory services, £1.3 million from contract manufacturing and £0.6 million from product sales, with a market value of roughly £39 million.